The therapies we develop are based on the cooperation of scientists and clinicians from the very beginning, meeting the expectations of modern veterinary medicine. As a result, the technologies we develop are adapted to the needs of the attending physician and his patients. We opt for the creation of a “tailor-made” therapy for the patient, fully adapted to the species, age and condition of the treated animal. In the case of ophthalmic treatment, the Institute supports the doctor with its clinical experience. In the case of orthopedic treatment  lek. wet. Mateusz Hecold supports The Institute with his knowledge and clinical experience.

Mateusz Hecold, VS, PhD (Dr n. wet.)

Mateusz Hecold, during the years 2004-2017, a veterinary physician and academic teacher at the Horse Clinic of the Warsaw University of Life Sciences, assistant professor and head of the Radiological Laboratory at the Department of Surgery, part of the Department of Large Animal Diseases with the Horse Clinic, Faculty of Veterinary Medicine, Warsaw University of Life Sciences (WULS). In 2016, he defended his doctoral dissertation on the impact of training on changes in the bones shape in young half-blooded horses, thus obtaining a doctorate in veterinary sciences. Dr. Hecold holds the title of a specialist in equine diseases, a specialist in veterinary radiology, a doctor of the Polish Equestrian Federation (PZJ) and a doctor of the International Equestrian Federation (FEI). Since 2016, a guardian and veterinary consultant in a sports stable of racehorses in the United Arab Emirates.
In the fields of hypiatrics, which Dr. n. Vet. Mateusz Hecold works daily in orthopedics, regeneration therapies for joints and tendons (IRAP, stem cells, PRP), physical therapy (high-energy laser therapies, shock wave theraphy and sonotherapy).

Research activity of Mateusz Hecold is documented by the following scientific publications:

Cywińska A., Szarska E., Gorecka R., Witkowski L., Hecold M., Berezowski A., SchollenbergerA., Winnicka A.: Acute chase protein concentrations after limited distance and long distance endurance rides In horses. Research in Veterinary Science 2012, 93: 1402-1406

Cywińska A., Szarska E., Gorecka R., Witkowski L., Wyszyńska Z., Hecold M., Berezowski A., Schollenberger A., Winnicka A.: Lumphocyte proliferation activity after limited (light class) and long (CEI) distance endurance rides in horses. Central European Journal of Immunology 2012; 37 (4): 326-331

K.Marycz, J.Kolanowski, J.Grzesiak, M.Hecold, O.rac, H. Tetrycz Application of gold nanoparticles (AuNPS) of different concentrations to improve the therapeutic potential of autologous conditioned serum (ACS) – potential implications for equine regenerative medicine, Journal of Nanomaterials

Developed orthopedic therapies

  • 1. Autologous stem cells isolated from adipose tissue

    ASCs / SIRT1 + stem cells are isolated from a fragment of the patient’s subcutaneous fat harvested under sterile conditions. Then they are multiplied in order to achieve a therapeutic dose in a short time period, in accordance with the recommendations of the International Society of Cellular Therapy. Cells are also subjected to a specialized biotechnological procedure in order to activate the SIRT1 marker which increases their regenerative abilities. The therapeutic potential of ASCs / SIRT1 + cells is based on their high immunomodulatory activity, thanks to which they effectively and permanently reduce the inflammatory reaction. Additionally, the cultivate ASCs / SIRT1 + cells activate regulatory T lymphocytes (Tregs), which contributes to the prolonged anti-inflammatory effect. ASCs / SIRT1 + cells are characterized by INCREASED activity of the CD105 marker, therefore they are characterized by high phenotypic plasticity. The cultivation of ASCs / SIRT1 + cells is performed by a qualified team of biotechnologists and doctors, which ensures the safety and effectiveness of therapy.

    • Intra-articular therapy in patients diagnosed with osteoarthritis, – intra-articular therapy in patients with a defect in the articular surface (loss of intra-articular hyaline cartilage)
    • Therapy of lesions in cartilage structures other than articular cartilage, e.g. meniscus, – acceleration of tendon and muscle structures healing (interosseous muscle, tendons and ligaments).

    Skuteczność komórek ASCs/SIRT1+ w leczeniu mięśnia międzykostnego opisuje jedna z naszych publikacji:

    Kornicka-Garbowska K, Pędziwiatr R, Woźniak P, Kucharczyk K, Marycz K. Microvesicles isolated from 5-azacytidine-and-resveratrol-treated mesenchymal stem cells for the treatment of suspensory ligament injury in horse-a case report. Stem Cell Res Ther. 2019;10(1):394. Published 2019 Dec 18. doi:10.1186/s13287-019-1469-5

  • 2. Regenerative microvesicles (Microvesicles LNC +)

    Extracellular membrane micro fragments (microvesicles-LNC +) are isolated by applying a specialized method developed by MIMT, designed for their separation from adipose stem cells. Microvesicles- LNC + are rich in growth factors, i.e. FGF, VFGF or EGF as well as morphogenetic proteins 2 (BMP-2), as a consequence they effectively initiate and induce the regeneration process of damaged tissues. Microvesicles – LNC + are rich in both micro RNA (miRNA) and long non-coding RNA molecules (lncRNA), therefore they are characterized by high regulatory capacity and a lasting therapeutic effect.

    • acceleration of the healing processes of tendon and muscle structures, with particular emphasis on healing tissue loss in the interosseous muscle, tendons and ligaments – during the injection carried out under ultrasound control, Microveiscles are directed precisely to the place of the injury
    • intra-articular therapy in patients diagnosed with osteoarthritis

  • 3. Regenerative serum (RegMedSerum)

    It is a personalized biological medicine based on the patient’s autologous blood. The whole blood collected from the patient is subjected to fractionation and physicochemical stimulation (magnetic field and magnetic bionanoparticles), as a result morphotic cells release a high concentration of pro-regenerative factors such as IGF-1, IL-10, TGF-β1 and GELSOLINE. As a consequence of advanced modulation of whole blood, thrombocytes and stem cells synthesizing an increased amount of growth factors and anti-inflammatory cytokines are activated. The serum supports the regeneration of damaged tissues and reduces the pain. The therapy stimulates the regenerative properties of the patient’s organism in a natural and safe manner.

    • intra-articular therapy for patients diagnosed with osteoarthritis
    • intra-articular therapy for patients with a defect of articular surface (loss of intra-articular hyaline cartilage)
    • supporting the treatment of muscle injuries
    • supporting the treatment of tendon structures
    • pain relief
    • arthritis

  • 4. Personalized autologous intra-articular implants (Nova-joint)

    Nova-joint autologous biological implants are an innovative biotechnological solution based on the isolation of selected autologous fractions of growth factors from the patient’s blood and enclosing them in liposomal micelles together with autologous stem cells, hyaluronic acid or any other drug prescribed by the attending physician. Nova-joint is an advanced, personalized therapeutic procedure. The developed technology allows us to create a personalized implant that is characterized by prolonged action and drug release for up to 6 months without the need for repeated administration. Nova-joint is a personalized regenerative therapy for joints with a prolonged effect.

    • the therapy is especially recommended for patients struggling with chronic osteoarthritis as, due to the prolonged release of the anti-inflammatory agent, it extends the therapeutic effect after intra-articular administration of drugs, and consequently prolongs the time between successive injections.
    • personalized autologous intra-articular implants reduce the risk of complications related to the frequent breaching of the articular capsule during repeated injections in a short period of time and, of possible complications related to joint contamination.

  • 5. PRP - 3G 3rd generation Platelet rich plasma (Nova-joint)

    PRP_3G has been successfully utilized in veterinary and human medicine for several years now. PRP_3G  is a biological medicine obtained from the patient’s own blood, which makes the therapy completely safe. The blood sample is processed in the laboratory by separating individual morphotic elements and enriching the plasma with thrombocytes. The isolated thrombocytes are subjected to modulation of their metabolic activity under special physicochemical conditions, as a result they selectively produce growth factors. Based on the conducted research, it was determined that thrombocytes contain as many as 60 biologically active substances with pro-regenerative properties (so-called growth factors), 90% of which are released from cells within an hour of their activation which takes place directly in the patient’s body. Valuable compounds support the process of tissue reconstruction and reduce inflammation.

    • supporting the treatment of muscle injuries,- supporting the treatment of tendon structures
    • intra-articular therapy for patients diagnosed with osteoarthritis
    • Arthritis